Money talks: BioNTech spends $205 million to jump the FDA queue

MAINZ, Germany, November 10, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that it has entered into an agreement to acquire a US Food and Drug Administration (“FDA”) Priority Review Voucher (“PRV”) from Scholar Rock, Inc. (Nasdaq: SRRK, “Scholar Rock”) for a total cash consideration of $205 million.

A PRV grants FDA priority review for a single application, which reduces the target FDA review timeline and could lead to expedited approval. BioNTech intends to use the PRV to support a future filing of an asset in its late-stage oncology pipeline. The transaction is subject to customary closing conditions, including clearance under the Hart-Scott Rodino (“HSR”) Antitrust Improvements Act.

https://www.biontech.com/int/en/home/mediaroom/news/statements/2026/11/BioNTech-to-Acquire-US-FDA-Priority-Review-Voucher.html